Caitlin Fierheller, PhDPostdoctoral Research Fellow in Women’s Precision Prevention Email: c.fierheller@qmul.ac.ukProfileResearchPublicationsProfileI joined the Women’s Precision Prevention (WPP) team with Prof Ranjit Manchanda as a postdoctoral research associate in February 2023. I am currently working across clinical trials in the WPP team which focus on population-based genetic testing, targeted screening, cancer prevention (including surgical) and health economics. I am a co-investigator on the PROTECT-C (Population based germline testing for early detection and prevention of cancer) and DETECT-2 (Direct to patient testing at cancer diagnosis for precision prevention-2). I also work on the Jewish Hereditary Cancer Review, PRESCORES (Preventing Endometrial Cancers: Comparing Risk-Reducing Strategies), PROTECTOR (Prevention ovarian cancer through early excision of tubes and late ovarian removal), and other studies. I completed my PhD in Human Genetics at McGill University, Montreal, Canada in 2023. My research focused on the molecular genetics of germline potentially pathogenic variants in DNA repair pathway genes in familial ovarian cancer. I obtained my BSc in 2016 in Genetics and Biochemistry from Western University, London, Canada.ResearchResearch Interests:Cancer prevention Cancer genetics Population-based genetic testingPublications Fierheller C, Sarig K, Oxley S et al. (2024). BRCA awareness and testing experience in the UK Jewish population: A qualitative study. nameOfConference DOI: 10.1016/j.ygyno.2024.07.238 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/100560 Fierheller C, Gootzen T, Kalra A et al. (2024). BRCA1 and BRCA2 information provision online: An occasion for improvement. nameOfConference DOI: 10.1016/j.ygyno.2024.07.234 QMRO: qmroHref Manchanda R, Wei X, Sun L et al. (2024). Cost-effectiveness analysis of cancer susceptibility gene-specific prevention strategies for ovarian and breast cancer. nameOfConference DOI: 10.1016/j.ygyno.2024.07.233 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/100488 Fierheller C, Sun L, Wei X et al. (2024). Population-based BRCA1 and BRCA2 genetic testing is cost-effective in Canada. nameOfConference DOI: 10.1016/j.ygyno.2024.07.067 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/100552 Sun L, Wei X, Fierheller CT et al. (2024). Economic Evaluation of Population-Based BRCA1 and BRCA2 Testing in Canada. nameOfConference DOI: 10.1001/jamanetworkopen.2024.32725 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/98325 Manchanda R (2024). Online Provision of BRCA1 and BRCA2 Health Information: A Search Engine Driven Systematic Web-Based Analysis. nameOfConference DOI: 10.3390/cancers16132324 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/97698 Manchanda R, Sun L, Wei X et al. (2024). Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer. nameOfConference DOI: 10.6004/jnccn.2023.7331 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/95917 Oxley S, Manchanda R (2024). BRCA awareness and testing experience in the UK Jewish population: a qualitative study. nameOfConference DOI: 10.1136/jmg-2023-109576 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/95916 Oxley S, Manchanda R (2024). Utility Scores for Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy: Mapping to EQ-5D. nameOfConference DOI: 10.3390/cancers16071358 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/95918 Sideris M, Brincat MR, Blyuss O et al. (2024). 1033 Validation of P-POSSUM scale in ovarian cancer (OC) cytoreductive surgery. Poster and E-Posters DOI: 10.1136/ijgc-2024-esgo.766 QMRO: qmroHref Gootzen TA, Kalra A, Sarig K et al. (2024). 405 Analysis of BRCA1 and BRCA2 information provision online. Poster and E-Posters DOI: 10.1136/ijgc-2024-esgo.884 QMRO: qmroHref Sun L, Wei X, Fierheller CT et al. (2024). 406 Population-based BRCA1 and BRCA2 testing in Canada: an economic evaluation. Young Investigator Session DOI: 10.1136/ijgc-2024-esgo.66 QMRO: qmroHref Wei X, Sun L, Slade E et al. (2024). 443 Cost-effectiveness analysis of cancer susceptibility gene-specific prevention strategies for ovarian and breast cancer. Oral Sessions DOI: 10.1136/ijgc-2024-esgo.50 QMRO: qmroHref Kalra A, Gootzen TA, Fierheller CT et al. (2024). 461 HBOC and lynch syndrome: ai-powered multi-platform analysis of social media activity. Poster and E-Posters DOI: 10.1136/ijgc-2024-esgo.503 QMRO: qmroHref Oxley S, Sia J, Samuels A et al. (2024). 583 Experiences of women following risk-reducing early-salpingectomy and delayed-oophorectomy and salpingo-oophorectomy on the PROTECTOR trial: a qualitative study. Poster and E-Posters DOI: 10.1136/ijgc-2024-esgo.895 QMRO: qmroHref Oxley S, Wei X, Sideris M et al. (2024). 948 EQ-5D utility scores for risk-reducing mastectomy and risk-reducing salpingo-oophorectomy: mapping from SF-12 and SF-36. Poster and E-Posters DOI: 10.1136/ijgc-2024-esgo.904 QMRO: qmroHref Wei X, Sun L, Slade E et al. (2024). Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer. nameOfConference DOI: 10.1001/jamanetworkopen.2023.55324 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/94579 Wei X, Sun L, Slade E et al. (2023). EE675 Cost-Effectiveness Analysis of Cancer Susceptibility Gene-Specific Prevention and Surveillance Strategies for Ovarian and Breast Cancer. nameOfConference DOI: 10.1016/j.jval.2023.09.940 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/93539 Sobocan M, Chandrasekaran D, Sideris M et al. (2024). Patient decision aids in mainstreaming genetic testing for women with ovarian cancer: A prospective cohort study. nameOfConference DOI: 10.1111/1471-0528.17675 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/91563 Alenezi WM, Fierheller CT, Serruya C et al. (publicationYear). Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases. nameOfConference DOI: 10.3389/fonc.2023.1111191 QMRO: qmroHref Fierheller CT, Alenezi WM, Serruya C et al. (publicationYear). Molecular Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene. nameOfConference DOI: 10.3390/genes14020277 QMRO: qmroHref Alenezi WM, Milano L, Fierheller CT et al. (publicationYear). The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population. nameOfConference DOI: 10.3390/cancers14092251 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/93779 Alenezi WM, Fierheller CT, Revil T et al. (publicationYear). Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic BRCA1 Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic BRCA1 and BRCA2 Variants. nameOfConference DOI: 10.3390/genes13040697 QMRO: qmroHref Fierheller CT, Guitton-Sert L, Alenezi WM et al. (2021). A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene. nameOfConference DOI: 10.1186/s13073-021-00998-5 QMRO: qmroHref Fierheller CT, Alenezi WM, Tonin PN (publicationYear). The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families. nameOfConference DOI: 10.3390/cancers13143406 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/93792 Alenezi WM, Fierheller CT, Recio N et al. (publicationYear). Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers. nameOfConference DOI: 10.3390/genes11080856 QMRO: qmroHref